Skip to main content

Tokai Pharmaceuticals Inc (NASDAQ:TKAI) Investor Investigation Over Potential Violations Of Securities Laws Announced

  • If you purchased shares of Tokai Pharmaceuticals Inc (NASDAQ:TKAI), you have certain options and you should contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this case, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Site Members can sign up for company wide alerts

Investigation Overview

July 28, 2016 (Update) - On July 26, 2016, Tokai Pharmaceuticals Inc announced that it was ending a late-stage trial of galeterone, its potential prostate cancer therapy. Tokai Pharmaceuticals Inc stated that it did not believe the phase 3 study would meet its primary endpoint.Shares of Tokai Pharmaceuticals Inc (NASDAQ:TKAI) declined from $18.39 per share in September 2014 to as low ...



You must register (for free) or login to view the entire investigation.